View Older Stories View More Recent Stories

May 16, 2018 07:32AM Sangamo Therapeutics (SGMO) & Sanofi (SNY) Company, Bioverativ Inc., Report FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
May 16, 2018 05:50AM Sanofi (SNY) & Regeneron (REGN) Report Dupixent (dupilumab) Showed Positive Phase 3 Results in Adolescents with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis
May 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 01:00AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 1, 2018 07:06AM Sanofi (SNY) and Regeneron (REGN) to Lower Net Price of Praluent; Praluent will become Exclusive PCSK9 inhibitor Therapy on Express Scripts (ESRX) National Formulary
May 1, 2018 07:00AM Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients
Apr 30, 2018 05:48AM Regeneron (REGN) Reports Acceptance for FDA Priority Review of BLA for Cemiplimab
Apr 30, 2018 01:02AM Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 30, 2018 01:01AM Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 30, 2018 01:00AM FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 3, 2018 05:48AM Regeneron (REGN) & Sanofi (SNY) Report EMA to Review Cemiplimab as Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 3, 2018 05:44AM Regeneron (REGN) & Sanofi (SNY) Report EMA to Review DUPIXENT (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma
Apr 3, 2018 01:00AM Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
Apr 3, 2018 01:00AM Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
Mar 12, 2018 05:41AM Regeneron (REGN) and Sanofi (SNY) Announce Praluent Met Primary Endpoint of Reducing Cardiovascular Events
Mar 10, 2018 09:03AM Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Mar 10, 2018 09:03AM Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Mar 10, 2018 09:02AM Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Mar 10, 2018 09:02AM Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Mar 10, 2018 09:01AM Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Mar 10, 2018 09:01AM Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Mar 10, 2018 09:00AM Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Mar 10, 2018 09:00AM Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Mar 2, 2018 05:49AM Regeneron (REGN) & Sanofi (SNY) Announce DUPIXENT Accepted for FDA Review
Mar 2, 2018 01:01AM Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
Mar 2, 2018 01:01AM Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
Mar 2, 2018 01:00AM Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
Feb 8, 2018 06:23AM Sanofi (SNY) Commences Tender Offer for Acquisition of Bioverativ (BIVV)
Feb 8, 2018 05:56AM Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
Feb 8, 2018 05:56AM Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
Feb 8, 2018 05:55AM Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
Jan 22, 2018 09:29AM Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
Jan 22, 2018 05:35AM Sanofi (SNY) to Acquire Bioverativ (BIVV) for $11.6B
Jan 22, 2018 01:10AM Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 22, 2018 01:04AM Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 8, 2018 07:03AM Sanofi (SNY), Regeneron (REGN) to accelerate, expand investment for cemiplimab and dupilumab development programs
Jan 8, 2018 07:01AM Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
Jan 8, 2018 07:01AM Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
Jan 8, 2018 07:00AM Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
Jan 8, 2018 06:21AM Evotech & Aperion Announce First Milestone Achievement in Immuno-Oncology Alliance with Sanofi (SNY)
Jan 8, 2018 05:53AM Alnylam Pharma (ALNY) and Sanofi (SNY) Report Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Jan 7, 2018 03:01PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Jan 7, 2018 03:01PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Jan 7, 2018 03:00PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Dec 18, 2017 07:04AM Sanofi (SNY) and Alnylam (ALNY) Submit EU Marketing Authorization Application for Patisiran to Treat hATTR amyloidosis
Dec 18, 2017 07:04AM Alnylam Pharma (ALNY) & Sanofi (SNY) Announce Marketing Authorisation Application to EMA for Patisiran for Treatment of Hereditary ATTR Amyloidosis
Dec 18, 2017 07:01AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 18, 2017 07:01AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
View More Recent Stories View Older Stories